GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (STU:0VQ) » Definitions » Policy Acquisition Expense

PureTech Health (STU:0VQ) Policy Acquisition Expense


View and export this data going back to 2020. Start your Free Trial

What is PureTech Health Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


PureTech Health Business Description

Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.